Advice
in the absence of a submission from the holder of the marketing authorisation:
carfilzomib (Kyprolis®) is not recommended for use within NHSScotland.
Indication under review: In combination with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice626KB (PDF)
Medicine details
- Medicine name:
- carfilzomib (Kyprolis)
- SMC ID:
- SMC2484
- Indication:
In combination with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 April 2022